创新消费力| 君实生物: 开启免疫治疗2.0时代

北京商报
Aug 05

当国产PD-1抑制剂将癌症治疗费用大幅拉低,曾被高价药阻隔的消费需求正不断释放。2025年,迎来创新药发展的十年节点。我国创新药企通过持续研发创新,让更多新药“飞入寻常百姓家”。同时,国产创新药凭借硬实力开始常态化“出海”,在国际市场的知名度越来越高。手握国产首个PD-1单抗的君实生物,正是蓬勃发展的本土创新药企的典型代表。中国创新药企从“仿制跟随”到“源头创新”,在特定疾病领域已实现并跑乃至领跑...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10